Clinical Trial Update: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Blinatumomab alone versus Blinatumomab with Nivolumab in patients with first-relapse B-cell acute lymphoblastic leukemia, with recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING